0000950170-24-077482.txt : 20240625 0000950170-24-077482.hdr.sgml : 20240625 20240625181501 ACCESSION NUMBER: 0000950170-24-077482 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240621 FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scots-Knight Denise CENTRAL INDEX KEY: 0001297000 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38452 FILM NUMBER: 241070166 MAIL ADDRESS: STREET 1: C/O IDENIX PHARMACEUTICALS, INC. STREET 2: 60 HAMPSHIRE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Pollard-Knight Denise DATE OF NAME CHANGE: 20040712 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mereo BioPharma Group plc CENTRAL INDEX KEY: 0001719714 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF BUSINESS PHONE: 4403330237300 MAIL ADDRESS: STREET 1: ONE CAVENDISH PLACE STREET 2: FOURTH FLOOR CITY: LONDON STATE: X0 ZIP: W1G0QF FORMER COMPANY: FORMER CONFORMED NAME: Mereo Biopharma Group plc DATE OF NAME CHANGE: 20171016 4 1 ownership.xml 4 X0508 4 2024-06-21 0001719714 Mereo BioPharma Group plc MREO 0001297000 Scots-Knight Denise C/O MEREO BIOPHARMA GROUP PLC 4TH FLOOR, ONE CAVENDISH PLACE LONDON X0 W1G 0QF UNITED KINGDOM true true false false Chief Executive Officer false American Depositary Shares representing Ordinary Shares 2024-06-21 4 M false 282090 0 A 842503 D Performance Based Restricted Stock Unit 0 2024-06-21 4 M false 282090 0 A 2024-06-21 2025-01-25 American Depository Shares 282090 188060 D Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. Represents performance-based restricted stock unit ("PSU") earned under the issuer's 2019 Employee Incentive Plan (the "Plan") that vested on June 21, 2024 based on satisfaction of ADS price threshold values over a two year performance period (expiring on January 1, 2025). Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. Includes 1,200 ADSs jointly owned by Reporting person and her spouse. /s/ Christine Fox, by power of attorney 2024-06-25